B&KHKSE:02396 -0.26%8 Dividend Yield % is 0.00% as of Jul. 09, 2026. GuruFocus rates HKSE:02396 with a GF Score™ of 8/100. The stock has 1 warning sign investors should review. Among 153 Biotechnology companies, B&K ranks worse than 653594.12% on this metric.
As of today (2026-07-09), the Trailing Annual Dividend Yield of B&K is 0.00%.
The historical rank and industry rank for B&K's Dividend Yield % or its related term are showing as below:
HKSE:02396's Dividend Yield % is not ranked *
in the Biotechnology industry.
Industry Median: 1.44 * Ranked among companies with meaningful Dividend Yield % only.
The growth rate is calculated with least square regression.
For more information regarding to dividend, please check our Dividend Page.
* Please note that "special dividend" is not included in the calculation of dividend per share and related fields.
B&K (HKSE:02396) Dividend Yield % Explanation
Over the long term, the return from dividends has been a significant contributor to the total returns produced by equity securities. Studies by Elroy Dimson, Paul Marsh, and Mike Staunton of Princeton University (2002) found that a market-oriented portfolio, which included reinvested dividends, would have generated nearly 85 times the wealth generated by the same portfolio relying solely on capital gains.
Dividends may also qualify a lower tax rate for investors.
In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.
The historical data trend for B&K's Dividend Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
B&K Dividend Yield % Chart
B&K Annual Data
Trend
Dec23
Dec24
Dec25
Dividend Yield %
0.00
0.00
0.00
B&K Quarterly Data
Dec23
Dec24
May25
Sep25
Dec25
Dividend Yield %
0.00
0.00
0.00
0.00
0.00
HKSE:02396 vs VRTX, REGN, ALNY: Dividend Yield % Comparison
For the Biotechnology subindustry, B&K's Dividend Yield %, along with its competitors' market caps and Dividend Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
B&K Dividend Yield % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, B&K's Dividend Yield % distribution charts can be found below:
* The bar in red indicates where B&K's Dividend Yield % falls into.
B&K (HKSE:02396) has a Dividend Yield % of 0.00% as of Jul. 09, 2026. Dividend yield is the ratio of company dividends to the share price. View historical data on B&K and its competitors. According to the industry distribution chart, B&K ranks #999999 out of 153 companies in the Biotechnology industry.
Is B&K's Dividend Yield % too high?
B&K's current Dividend Yield % is 0.00%. Based on the distribution chart, B&K ranks #999999 out of 153 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, B&K has a GF Score™ of 8/100, reflecting its overall financial health beyond just this single metric.
How does B&K's Dividend Yield % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, B&K ranks #999999 out of 153 companies for Dividend Yield %. This places B&K in the lower half of its industry. The industry median Dividend Yield % is 1.44. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Dividend Yield % for a Biotechnology company?
The median Dividend Yield % among Biotechnology companies is 1.44, based on 153 companies in the industry. Companies in the top quartile (top 25%) have a Dividend Yield % significantly above this median, while those in the bottom quartile fall well below. However, Dividend Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Dividend Yield % mean?
A high Dividend Yield % can signal that a stock is expensive relative to its fundamentals. Dividend yield is the ratio of company dividends to the share price. View historical data on B&K and its competitors. For the Biotechnology industry, the median Dividend Yield % is 1.44 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. B&K's current Dividend Yield % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is B&K stock overvalued right now?
B&K (HKSE:02396) has a current Dividend Yield % of 0.00%. The current Dividend Yield % is 0.00%. B&K's overall GF Score™ is 8/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Dividend Yield % calculated?
Dividend Yield % is calculated from a company's financial statements. For B&K (HKSE:02396), the current Dividend Yield % is 0.00% as of Jul. 09, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
B&K Corp Ltd is a China-based biopharmaceutical company committed to developing therapies with an emphasis on protein drugs for indications with medical needs and market opportunities. The company prominently focuses on the discovery, development and commercialization of therapies for wound healing, currently PDGF drugs. Its pipeline consisted of ten candidates, seven of which are PDGF candidates, including two Core Products, namely Pro-101-1 for the treatment of thermal burns and Pro-101-2 for the treatment of DFUs, which are rhPDGF-BB drugs. The company operates in a single reportable segment: the research and development of biopharmaceutical products. Geographically, the company generates all its revenue from Chinese Mainland.
8GF Score
Get the complete analysis for HKSE:02396
Dividend Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:02396 has been successfully added to your 